The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Brachytherapy


Psychiatry related information on Brachytherapy


High impact information on Brachytherapy

  • The treatment protocol involved surgery, partial brain external-beam radiotherapy (59.4 Gy in 33 fractions), and stereotactic brachytherapy with temporary high-activity iodine 125 sources giving an additional 50 Gy to the tumor bed [8].
  • The results were compared with caesium-137 brachytherapy; both isotopes were given in combination with high-dose fractionated pelvic radiotherapy [9].
  • Specifically, key issues include dose escalation; the relative benefit of alternative forms of RT (ie, brachytherapy and protons); target localization; the use, timing, and duration of androgen deprivation; and the need for pelvic nodal irradiation [10].
  • PATIENTS AND METHODS: Patients who had been evaluated previously at a median of 2.6 years after radical prostatectomy (RP), external radiation (three-dimensional conformal radiation therapy [3-D CRT]), or brachytherapy (BT) were recontacted at a median of 6.2 years after treatment [11].
  • Patients were treated with external irradiation and intracavitary brachytherapy, and most received concurrent weekly cisplatin [12].

Chemical compound and disease context of Brachytherapy

  • Sexual function was evaluated in 34 patients with low-risk prostate cancer (PSA < or = 10, Gleason score < or = 6, clinical stage T1/T2) undergoing brachytherapy in a phase III prospective randomized trial comparing iodine-125 ((125)I) to palladium-103 ((103)Pd) [13].
  • METHODS AND MATERIALS: Between September 1988 and June 1991, 23 patients were treated with interstitial Iridium-192 high dose-rate brachytherapy immediately followed by interstitial hot water hyperthermia [14].
  • PURPOSE: We have reviewed the results of 165 T1 and T2 squamous cell carcinomas of the faucial arch treated by definitive irradiation including or not Iridium 192 brachytherapy to ascertain whether a significant relationship existed between Iridium implantation, local control, complications, and survival [15].
  • A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy [16].
  • CONCLUSION: Review of early data suggests that intraoperative 125I vicryl mesh brachytherapy in high-risk Stage I NSCLC is potentially effective and well tolerated, with no significant decline in measurable pulmonary function studies and no increase in postoperative complications [17].

Biological context of Brachytherapy

  • PATIENTS AND METHODS: In a retrospective way we report on 163 patients' PSA kinetics after EBT alone to 68 Gy or EBT first and a brachytherapy boost up to 75 or 85 Gy [18].
  • Differential effects of CLDR and PDR brachytherapy on cell cycle progression in a syngeneic rat prostate tumour model [19].
  • Considering the additional HDR brachytherapy rectum protection takes the highest priority in definitive treatment-the requirements are best met in supine position [20].
  • In contrast to sham-treated controls, the aneuploid cell fraction with G2/M DNA content was significantly increased (p < 0.05) after initiation of both, CLDR and PDR brachytherapy [19].
  • BACKGROUND: The objective of this study was to assess the value of apoptosis protease-activating factor 1 (APAF-1) as a predictive marker of response in rectal tumors treated with preoperative, high-dose-rate endorectal brachytherapy [21].

Anatomical context of Brachytherapy


Associations of Brachytherapy with chemical compounds

  • Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy [27].
  • Pelvic radiation consisted of external-beam therapy to a dose of 39.6 Gy, followed by brachytherapy with cesium 137 tandem and ovoid insertions to deliver 80 Gy to point A and 55 Gy to point B [28].
  • METHODS: A retrospective analysis of these patients who were treated either with endoscopic biliary stenting followed by external beam radiotherapy and internal iridium-192 brachytherapy (n = 28) or with stenting alone (control group; n = 28) [29].
  • The ACh-induced changes in artery diameter before and after brachytherapy were -1.5 +/- 0.5 mm and -0.5 +/- 0.3 mm (p < 0.0001) for the first vessels and -1.4 +/- 0.3 mm and -0.4 +/- 0.2 mm (p < 0.01) for the second vessels, respectively [30].
  • Immediately following a conventional brachytherapy dose and removal of the iridium seeds the tumors were heated again in a second treatment [31].

Gene context of Brachytherapy

  • The results of one such experimental measurement and analysis are here reported for a new design of 103palladium source, model MED3633 (North American Scientific, Inc.). By AAMP Task Group #43 recommendations, the reference material for brachytherapy dosimetry is liquid water [32].
  • Radiation dose measurements with alanine/agarose gel and thin alanine films around a 192Ir brachytherapy source, using ESR spectroscopy [33].
  • We conclude that p53 expression and function are normal or increased in r-VSMCs and may underlie the success of brachytherapy [34].
  • Each brachytherapy patient was matched with one external-beam RT (ERT) patient derived from a reference group of 1,388 patients treated with standard BCT [35].
  • Inverse treatment planning based on MRI for HDR prostate brachytherapy [36].

Analytical, diagnostic and therapeutic context of Brachytherapy


  1. Direct stenting versus direct stenting followed by centered beta-radiation with intravascular ultrasound-guided dosimetry and long-term anti-platelet treatment: results of a randomized trial: Beta-Radiation Investigation with Direct Stenting and Galileo in Europe (BRIDGE). Serruys, P.W., Wijns, W., Sianos, G., de Scheerder, I., van den Heuvel, P.A., Rutsch, W., Glogar, H.D., Macaya, C., Materne, P.H., Veldhof, S., Vonhausen, H., Otto-Terlouw, P.C., van der Giessen, W.J. J. Am. Coll. Cardiol. (2004) [Pubmed]
  2. Liver transplantation for unresectable perihilar cholangiocarcinoma. Heimbach, J.K., Gores, G.J., Haddock, M.G., Alberts, S.R., Nyberg, S.L., Ishitani, M.B., Rosen, C.B. Semin. Liver Dis. (2004) [Pubmed]
  3. A predictive model of rectal tumor response to preoperative radiotherapy using classification and regression tree methods. Zlobec, I., Steele, R., Nigam, N., Compton, C.C. Clin. Cancer Res. (2005) [Pubmed]
  4. Permanent source brachytherapy for prostate cancer. American College of Radiology. ACR Appropriateness Criteria. Potters, L., Perez, C.A., Beyer, D.C., Blasko, J.C., Forman, J.D., Hussey, D.H., Lee, W.R., Paryani, S.B., Pollack, A., Roach, M., Scardino, P., Schellhammer, P., Leibel, S. Radiology. (2000) [Pubmed]
  5. A histologic study (including DNA quantification and Ki-67 labeling index) in uveal melanomas after brachytherapy with ruthenium plaques. Schilling, H., Sehu, K.W., Lee, W.R. Invest. Ophthalmol. Vis. Sci. (1997) [Pubmed]
  6. Permanent interstitial brachytherapy for the management of carcinoma of the prostate gland. Merrick, G.S., Wallner, K.E., Butler, W.M. J. Urol. (2003) [Pubmed]
  7. Early reduction in the aneuploidy at chromosomes 7 and 8 are significantly correlated with clinical effect in high-dose rate brachytherapy with external beam radiotherapy in localized prostate cancer. Kasahara, K., Taguchi, T., Inoue, K., Shuin, T., Kariya, S., Yoshida, S., Furihata, M. Int. J. Mol. Med. (2001) [Pubmed]
  8. Results of stereotactic brachytherapy used in the initial management of patients with glioblastoma. Loeffler, J.S., Alexander, E., Wen, P.Y., Shea, W.M., Coleman, C.N., Kooy, H.M., Fine, H.A., Nedzi, L.A., Silver, B., Riese, N.E. J. Natl. Cancer Inst. (1990) [Pubmed]
  9. Neutron brachytherapy is better than conventional radiotherapy in advanced cervical cancer. Maruyama, Y., Kryscio, R., van Nagell, J.R., Yoneda, J., Donaldson, E., Hanson, M., Beach, J.L., Feola, J.M., Martin, A., Parker, C. Lancet (1985) [Pubmed]
  10. Radiotherapy in the management of clinically localized prostate cancer: evolving standards, consensus, controversies and new directions. Speight, J.L., Roach, M. J. Clin. Oncol. (2005) [Pubmed]
  11. Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. Miller, D.C., Sanda, M.G., Dunn, R.L., Montie, J.E., Pimentel, H., Sandler, H.M., McLaughlin, W.P., Wei, J.T. J. Clin. Oncol. (2005) [Pubmed]
  12. Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. Grigsby, P.W., Siegel, B.A., Dehdashti, F., Rader, J., Zoberi, I. J. Clin. Oncol. (2004) [Pubmed]
  13. Short-term sexual function after prostate brachytherapy. Merrick, G.S., Wallner, K., Butler, W.M., Lief, J.H., Sutlief, S. Int. J. Cancer (2001) [Pubmed]
  14. Analysis of temperature distributions of interstitial hyperthermia using a hot water system. Stuecklschweiger, G., Arian-Schad, K.S., Kapp, D.S., Handl-Zeller, L., Hackl, A.G. Int. J. Radiat. Oncol. Biol. Phys. (1993) [Pubmed]
  15. Place of Iridium 192 implantation in definitive irradiation of faucial arch squamous cell carcinomas. Mazeron, J.J., Belkacemi, Y., Simon, J.M., Le Pechoux, C., Martin, M., Haddad, E., Piedbois, P., Calitchi, E., Strunski, W., Peynegre, R. Int. J. Radiat. Oncol. Biol. Phys. (1993) [Pubmed]
  16. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy. Vargas, C., Ghilezan, M., Hollander, M., Gustafson, G., Korman, H., Gonzalez, J., Martinez, A. J. Urol. (2005) [Pubmed]
  17. Intraoperative 125I brachytherapy for high-risk stage I non-small cell lung carcinoma. Chen, A., Galloway, M., Landreneau, R., d'Amato, T., Colonias, A., Karlovits, S., Quinn, A., Santucci, T., Kalnicki, S., Brown, D. Int. J. Radiat. Oncol. Biol. Phys. (1999) [Pubmed]
  18. PSA kinetics after external beam radiotherapy alone or combined with an iridium brachytherapy boost to deliver 85 grays to prostatic adenocarcinoma. Nickers, P., Coppens, L., Beauduin, M., Sabatier, J., Albert, A., de Leval, J., Deneufbourg, J.M. Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]. (2001) [Pubmed]
  19. Differential effects of CLDR and PDR brachytherapy on cell cycle progression in a syngeneic rat prostate tumour model. Harms, W., Weber, K.J., Ehemann, V., Zuna, I., Debus, J., Peschke, P. Int. J. Radiat. Biol. (2006) [Pubmed]
  20. Dose-volume histogram evaluation of prone and supine patient position in external beam radiotherapy for cervical and endometrial cancer. Pinkawa, M., Gagel, B., Demirel, C., Schmachtenberg, A., Asadpour, B., Eble, M.J. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. (2003) [Pubmed]
  21. The predictive value of apoptosis protease-activating factor 1 in rectal tumors treated with preoperative, high-dose-rate brachytherapy. Zlobec, I., Vuong, T., Compton, C.C. Cancer (2006) [Pubmed]
  22. Local vaginal anesthesia during high-dose-rate intracavitary brachytherapy for cervical cancer. Chen, H.C., Leung, S.W., Wang, C.J., Sun, L.M., Fang, F.M., Huang, E.Y., Wang, S.J., Yang, C.W. Int. J. Radiat. Oncol. Biol. Phys. (1998) [Pubmed]
  23. Malignant melanoma of the eyelid and palpebral conjunctiva treated with iodine-125 brachytherapy. Stannard, C.E., Sealy, G.R., Hering, E.R., Pereira, S.B., Knowles, R., Hill, J.C. Ophthalmology (2000) [Pubmed]
  24. Design and dosimetry of a novel 90Y beta source to prevent restenosis after angioplasty. Mück, K., Schmidt, W., Wexberg, P., Görz, W., Maurer, G., Gottsauner-Wolf, M. Int. J. Radiat. Oncol. Biol. Phys. (2000) [Pubmed]
  25. Ultrasound directed extrahepatic bile duct intraluminal brachytherapy. Minsky, B., Botet, J., Gerdes, H., Lightdale, C. Int. J. Radiat. Oncol. Biol. Phys. (1992) [Pubmed]
  26. Combined isodose curves of high-dose rate interstitial brachytherapy with external-beam radiation therapy in pancreatic carcinoma. Warszawski, N., Pfreundner, L., Bratengeier, K., Bohndorf, W., Feustel, H. Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]. (1992) [Pubmed]
  27. Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy. Potters, L., Torre, T., Ashley, R., Leibel, S. J. Clin. Oncol. (2000) [Pubmed]
  28. Pilot trial of cisplatin, radiation, and WR2721 in carcinoma of the uterine cervix: a New York Gynecologic Oncology Group study. Wadler, S., Beitler, J.J., Rubin, J.S., Haynes, H., McGill, F., Rozenblit, A., Goldberg, G., Cohen, C., Speyer, J., Runowicz, C. J. Clin. Oncol. (1993) [Pubmed]
  29. A retrospective comparison of endoscopic stenting alone with stenting and radiotherapy in non-resectable cholangiocarcinoma. Bowling, T.E., Galbraith, S.M., Hatfield, A.R., Solano, J., Spittle, M.F. Gut (1996) [Pubmed]
  30. Brachytherapy: potential therapy for refractory coronary spasm. Erne, P., Jamshidi, P., Juelke, P., Hafner, H.P., Thum, P., Resink, T. J. Am. Coll. Cardiol. (2004) [Pubmed]
  31. Interstitial hyperthermia in combination with brachytherapy. Coughlin, C.T., Douple, E.B., Strohbehn, J.W., Eaton, W.L., Trembly, B.S., Wong, T.Z. Radiology. (1983) [Pubmed]
  32. Dosimetric characterization of a new design 103 palladium brachytherapy source. Wallace, R.E., Fan, J.J. Medical physics. (1999) [Pubmed]
  33. Radiation dose measurements with alanine/agarose gel and thin alanine films around a 192Ir brachytherapy source, using ESR spectroscopy. Olsson, S., Bergstrand, E.S., Carlsson, A.K., Hole, E.O., Lund, E. Physics in medicine and biology. (2002) [Pubmed]
  34. Human vascular smooth muscle cells from restenosis or in-stent stenosis sites demonstrate enhanced responses to p53: implications for brachytherapy and drug treatment for restenosis. Scott, S., O'Sullivan, M., Hafizi, S., Shapiro, L.M., Bennett, M.R. Circ. Res. (2002) [Pubmed]
  35. Accelerated treatment of breast cancer. Vicini, F.A., Baglan, K.L., Kestin, L.L., Mitchell, C., Chen, P.Y., Frazier, R.C., Edmundson, G., Goldstein, N.S., Benitez, P., Huang, R.R., Martinez, A. J. Clin. Oncol. (2001) [Pubmed]
  36. Inverse treatment planning based on MRI for HDR prostate brachytherapy. Citrin, D., Ning, H., Guion, P., Li, G., Susil, R.C., Miller, R.W., Lessard, E., Pouliot, J., Huchen, X., Capala, J., Coleman, C.N., Camphausen, K., Ménard, C. Int. J. Radiat. Oncol. Biol. Phys. (2005) [Pubmed]
  37. Brachial arterial access: endovascular treatment of failing Brescia-Cimino hemodialysis fistulas--initial success and long-term results. Manninen, H.I., Kaukanen, E.T., Ikäheimo, R., Karhapää, P., Lahtinen, T., Matsi, P., Lampainen, E. Radiology. (2001) [Pubmed]
  38. Endovascular irradiation with the liquid beta-emitter Rhenium-188 to reduce restenosis after experimental wall injury. Wohlfrom, M., Kotzerke, J., Kamenz, J., Eble, M., Hess, B., Wöhrle, J., Reske, S.N., Hombach, V., Hanke, H., Höher, M. Cardiovasc. Res. (2001) [Pubmed]
  39. Results of hysterectomy in patients with bulky residual disease at the end of chemoradiotherapy for stage IB2/II cervical carcinoma. Azria, E., Morice, P., Haie-Meder, C., Thoury, A., Pautier, P., Lhomme, C., Duvillard, P., Castaigne, D. Ann. Surg. Oncol. (2005) [Pubmed]
  40. Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy. Zietman, A.L., Thakral, H., Wilson, L., Schellhammer, P. J. Urol. (2001) [Pubmed]
WikiGenes - Universities